AEON Biopharma Seeks Shareholder Nod for Critical Financing, Equity Deals

Ticker: AEON · Form: DEF 14A · Filed: Dec 29, 2025 · CIK: 1837607

Sentiment: mixed

Topics: Biopharma, Proxy Statement, Special Meeting, PIPE Financing, Convertible Notes, Equity Plan, Biosimilar Development

Related Tickers: AEON

TL;DR

**AEON needs these votes to survive and fund its BOTOX biosimilar, so expect a 'FOR' push or major dilution.**

AI Summary

AEON Biopharma, Inc. is holding a Special Meeting on January 21, 2026, to approve critical financing and equity proposals aimed at funding the development and potential commercialization of ABP-450, a biosimilar to BOTOX. The company seeks stockholder approval for a PIPE Financing Proposal, which includes the issuance and sale of 4,616,924 shares of Class A common stock, warrants to purchase 6,581,829 shares, and shares from True-Up Warrants. Additionally, AEON needs approval for an Exchange Proposal with Daewoong Pharmaceutical Co, Ltd., involving the exchange of outstanding senior secured convertible notes for shares of common stock or pre-funded warrants, a new senior secured convertible note in a principal amount of $1,500,000, and a warrant to purchase 8,000,000 shares. Both the PIPE Financing Proposal and the Exchange Proposal are mutually conditioned on each other's approval. The company also seeks to approve an Amended and Restated 2023 Incentive Award Plan to increase authorized shares and an Adjournment Proposal if necessary to solicit additional proxies. These transactions are crucial for AEON's strategic outlook and continued operations.

Why It Matters

This DEF 14A filing is critical for AEON Biopharma's future, as stockholder approval of the PIPE Financing and Exchange Proposals is essential to secure funding for the development and commercialization of ABP-450, a potential biosimilar to BOTOX. Failure to approve these proposals could severely impact the company's ability to advance its lead product candidate, potentially jeopardizing its competitive position against established players in the neurotoxin market. For investors, these votes directly influence the company's financial stability and growth prospects, while employees and customers are impacted by the continued viability and product pipeline of AEON Biopharma. The broader market will watch to see if AEON can successfully navigate these financing hurdles to bring a new biosimilar to market.

Risk Assessment

Risk Level: high — The risk level is high because the PIPE Financing Proposal and the Exchange Proposal are mutually conditioned, meaning failure to approve either one will prevent both critical transactions from closing. The filing explicitly states, 'The Second Closing (as defined below) and the Exchange (as defined below) will be consummated only if both the PIPE Financing Proposal and the Exchange Proposal are approved by our stockholders.' This interdependence creates significant execution risk for AEON Biopharma's funding strategy.

Analyst Insight

Investors should carefully review the full proxy statement and consider voting 'FOR' the PIPE Financing Proposal and the Exchange Proposal, as the Board recommends. Failure to approve these mutually conditioned proposals could severely impede AEON's ability to fund its ABP-450 development and commercialization, potentially leading to significant downside for current shareholders.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of AEON Biopharma's Special Meeting on January 21, 2026?

AEON Biopharma is holding a Special Meeting on January 21, 2026, to seek stockholder approval for a PIPE Financing Proposal, an Exchange Proposal with Daewoong Pharmaceutical Co, Ltd., an Amended and Restated 2023 Incentive Award Plan, and an Adjournment Proposal. These proposals are crucial for funding the development and potential commercialization of ABP-450.

What are the key financial proposals AEON Biopharma is asking stockholders to approve?

AEON Biopharma is asking stockholders to approve the PIPE Financing Proposal, which includes issuing 4,616,924 shares of common stock and warrants for 6,581,829 shares, and the Exchange Proposal, involving a new $1,500,000 senior secured convertible note and a warrant for 8,000,000 shares with Daewoong Pharmaceutical Co, Ltd.

Who is Robert Bancroft and what is his role at AEON Biopharma?

Robert Bancroft is the President, Chief Executive Officer, and Director of AEON Biopharma, Inc. He signed the Notice of Special Meeting of Stockholders on December 29, 2025, on behalf of the Board of Directors.

What are the risks if AEON Biopharma's stockholders do not approve the PIPE Financing and Exchange Proposals?

If AEON Biopharma's stockholders do not approve both the PIPE Financing Proposal and the Exchange Proposal, neither transaction will be consummated, as they are mutually conditioned. This would significantly hinder the company's ability to fund the development and commercialization of ABP-450, potentially impacting its strategic goals.

How does AEON Biopharma's Board of Directors recommend stockholders vote on the proposals?

AEON Biopharma's Board of Directors recommends that stockholders vote 'FOR' the approval of the PIPE Financing Proposal, 'FOR' the approval of the Exchange Proposal, 'FOR' the approval of the Equity Plan Proposal, and 'FOR' the Adjournment Proposal.

What is the significance of the NYSE American Company Guide in AEON Biopharma's proposals?

The NYSE American Company Guide is significant because AEON Biopharma is seeking stockholder approval for the PIPE Financing Proposal and the Exchange Proposal specifically for purposes of complying with its requirements, in addition to other general purposes.

What is the record date for voting at AEON Biopharma's Special Meeting?

The record date for stockholders entitled to notice of, and to vote at, AEON Biopharma's Special Meeting is the close of business on December 15, 2025. Only holders of record on this date can vote.

What is the Amended and Restated 2023 Incentive Award Plan for AEON Biopharma?

The Amended and Restated 2023 Incentive Award Plan is a proposal for AEON Biopharma to increase the number of shares of Common Stock authorized for issuance under the plan. This is intended to provide equity incentives for employees and directors.

How many shares of common stock were outstanding for AEON Biopharma as of the record date?

As of the record date, December 15, 2025, there were 12,105,902 shares of AEON Biopharma's Common Stock outstanding, with each share entitling the holder to one vote at the Special Meeting.

Where will AEON Biopharma's Special Meeting be held?

AEON Biopharma's Special Meeting will be held at the company's offices located at 5 Park Plaza, Suite 1750, Irvine, California 92614, on January 21, 2026, at 8:00 a.m. Pacific Time.

Industry Context

AEON Biopharma operates in the competitive biopharmaceutical sector, focusing on developing biosimilars. The market for biosimilars, particularly for high-value biologics like BOTOX, is growing due to patent expirations and the potential for cost savings. However, the development and commercialization of biosimilars require significant capital investment, rigorous regulatory approval processes, and strategic partnerships to navigate market entry and competition from established players.

Regulatory Implications

The company's success hinges on navigating the complex regulatory pathways for biosimilar approval, which requires extensive clinical trials and adherence to strict FDA guidelines. Any delays or setbacks in the regulatory process for ABP-450 could significantly impact AEON's financial projections and market entry timeline. Furthermore, the proposed financing and equity transactions are subject to shareholder approval and regulatory scrutiny.

What Investors Should Do

  1. Review the details of the PIPE Financing Proposal and the Exchange Proposal with Daewoong Pharmaceutical.
  2. Evaluate the proposed amendments to the Amended and Restated 2023 Incentive Award Plan.
  3. Consider the mutual conditionality of the PIPE and Exchange proposals.
  4. Assess the company's financial position and cash runway based on the latest filings (10-K and 10-Q).

Key Dates

Glossary

DEF 14A
A proxy statement filed with the U.S. Securities and Exchange Commission (SEC) by publicly traded companies. It contains information that the company is required to provide to its shareholders before their annual meeting, or a special meeting, at which they will vote on certain corporate actions. (This document outlines the proposals AEON Biopharma's shareholders will vote on, including financing and equity adjustments critical for the company's future.)
PIPE Financing
Private Investment in Public Equity. This is a way for public companies to raise capital by selling their securities directly to a private investor or a group of investors. (AEON is seeking shareholder approval for a PIPE financing involving the issuance of 4,616,924 shares of Class A common stock and warrants, crucial for funding its operations and development.)
Biosimilar
A biological product that is highly similar to a reference approved biological product in terms of safety, purity, and potency. Biosimilarity does not mean identical. (AEON's lead product candidate, ABP-450, is a biosimilar to BOTOX, positioning the company in a competitive but growing market segment.)
Senior Secured Convertible Notes
Debt instruments that are backed by collateral and can be converted into equity (shares) of the issuing company under certain conditions. (AEON is proposing an exchange of existing convertible notes for new notes and equity, indicating a restructuring of its debt obligations.)
True-Up Warrants
Warrants that may be issued to adjust the number of shares or exercise price of other warrants or securities based on certain pre-defined conditions or events. (These are part of the proposed PIPE financing, suggesting a mechanism to ensure a certain value or number of shares for investors.)
Pre-funded Warrants
Warrants that allow the holder to purchase shares at a nominal exercise price, effectively providing immediate ownership of the underlying shares upon exercise. (These are an option in the Exchange Proposal, offering flexibility to investors in the debt-to-equity conversion.)

Year-Over-Year Comparison

This DEF 14A filing focuses on upcoming shareholder votes for critical financing and strategic proposals, rather than a year-over-year financial performance comparison. The key information pertains to proposed share issuances (4,616,924 shares in PIPE, plus warrants), debt restructuring with Daewoong (including a $1,500,000 note and 8,000,000 warrants), and amendments to incentive plans. The previous filings (10-K for 2024 and 10-Q for Q3 2025) would provide the historical financial context against which the impact of these new proposals can be assessed.

Filing Stats: 4,779 words · 19 min read · ~16 pages · Grade level 14.2 · Accepted 2025-12-29 16:05:16

Key Financial Figures

Filing Documents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 4 PROXY STATEMENT SUMMARY 5 PROXY STATEMENT 6 QUESTIONS AND ANSWERS 6 BACKGROUND FOR THE SPECIAL MEETING AND PROPOSALS 12 MATTERS TO BE CONSIDERED AT SPECIAL MEETING 17 PROPOSAL 1 – THE PIPE FINANCING PROPOSAL 17 PROPOSAL 2 – THE EXCHANGE PROPOSAL 19 PROPOSAL 3 – THE EQUITY PLAN PROPOSAL 21 EXECUTIVE AND DIRECTOR COMPENSATION 32 EQUITY COMPENSATION PLAN INFORMATION 42 PROPOSAL 4 – THE ADJOURNMENT PROPOSAL 43

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 44 ADDITIONAL INFORMATION 48 APPENDIX A-1 – AEON BIOPHARMA, INC. AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (AS INCLUDED IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K FILED MARCH 24, 2025) APPENDIX A-2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (AS INCLUDED IN THE COMPANY'S ANNUAL REPORT ON FORM 10-K FILED MARCH 24, 2025) APPENDIX B-1 – AEON BIOPHARMA, INC. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 (AS INCLUDED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FILED NOVEMBER 14, 2025) APPENDIX B-2 – MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 (AS INCLUDED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FILED NOVEMBER 14, 2025) APPENDIX C – AEON BIOPHARMA AMENDED AND RESTATED 2023 INCENTIVE PLAN 3 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Proxy Statement contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact included in this Proxy Statement regarding our business strategy, plans, goal, and objectives are forward-looking statements, including without limitation statements regarding the Company's ability to consummate the Second Closing (as defined below) and the Exchange (as defined below) and its intent or ability to regain compliance with any applicable continued listing standards of the NYSE American Company Guide. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "intend," "budget," "target," "aim," "strategy," "estimate," "plan," "guidance," "outlook," "may," "should," "could," "will," "would," "will be," "will continue," "will likely result," and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company and management's beliefs and expectations based on current estimates and projections. While the Company believes these expectations, and the estimates and projections on which they are based, are reasonable and were made in good faith, these statements are subject to numerous risks and uncertainties, any of which could cause the Company's actual results, performance, or achievements, or industry results, to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which include, but are not limited to, the risks described in this Proxy Statement under the heading "Background for the Special Meeting and the Proposals," the risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, under the heading

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing